KRMD צמיחה צפויה ברווח נקי למניה השנה korumedical.com
KORU Medical Systems is developing partnerships with biologic manufacturers to simplify home infusion. The year-over-year shift in EPS, with the latest figure standing at 74.00, allows for an assessment of capital efficiency against the risks of regulatory delays and competition. Dominance in the mechanical pump segment for immunoglobulins creates a sustainable defensive moat and high patient loyalty.
פילוחים אנליטיים ודוחות נתונים של חברת korumedical.com (KRMD)
Steady cash flow from the sale of Freedom systems and consumables creates a solid operational foundation for KORU Medical Systems (KRMD). By analyzing the relative growth of net income per share over the year, an investor assesses EPS dynamics relative to the previous period, which allows for the timely recognition of fading leadership and the avoidance of a value trap during a phase of slowing market business activity.
